SCHEMBL15907124

SCHEMBL15907124

Cc1cc(C(N)=O)cc2nnc(C(C)(C)C)n12

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
KDM4E B2RXH2 2/20 0.34
AURKA O14965 1/20 0.34
CSF1R P07333 1/20 0.34
RET P07949 1/20 0.34
LTK P29376 1/20 0.34
CSNK1A1 P48729 1/20 0.34
CDK8 P49336 1/20 0.34
CLK2 P49760 1/20 0.34
CDK5 Q00535 1/20 0.34
ACVR1 Q04771 1/20 0.34
CLK4 Q9HAZ1 1/20 0.34
BRD4 O60885 1/20 0.34
LMNA P02545 1/20 0.33
MAPK13 O15264 2/20 0.32
RAF1 P04049 1/20 0.32
L3MBTL1 Q9Y468 1/20 0.31
PARP1 P09874 1/20 0.31
RIPK2 O43353 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15907105 0.86 MEN1 (0.37) MEN1KMT2AKDM4EMAPK13RAF1
SCHEMBL15907122 0.84 MEN1 (0.49) MEN1KMT2AAURKACSF1RRET
SCHEMBL15907103 0.81 MEN1 (0.34) MEN1KMT2A
SCHEMBL15907114 0.81 MEN1 (0.34) MEN1KMT2APARP1RIPK2
SCHEMBL15907092 0.81 MEN1 (0.34) MEN1KMT2ABRD4
SCHEMBL18323618 0.81 KDM4E (0.55) KMT2AKDM4EBRD4LMNAL3MBTL1
SCHEMBL15907097 0.79 MEN1 (0.33) MEN1KMT2A
SCHEMBL15907093 0.79 MEN1 (0.33) MEN1KMT2A
SCHEMBL15907120 0.79 MEN1 (0.35) MEN1KMT2AMAPK13RAF1
SCHEMBL15907090 0.78 TSHR (0.41) MEN1KMT2AKDM4ELMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9522910-B2 Protein kinase inhibitors (variants), use thereof in treating oncological diseases and a pharmaceutical composition based thereon Obshchestvo s ogranichennoy otvetstvennostyou “Fusion Pharma” (RU) 2016-12-20 US disclosed
US-20140213592-A1 Protein Kinase Inhibitors (Variants), Use Thereof in Treating Oncological Diseases and a Pharmaceutical Composition Based Thereon OBSHCHESTVO S OGRANICHENNOY OTVETSTVENNOSTYOU "FUSION PHARMA" (RU) 2014-07-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140213592-A1 Protein Kinase Inhibitors (Variants), Use Thereof in Treating Oncological Diseases and a Pharmaceutical Composition Based Thereon ABL1, ABL2, MAP3K6 MEN1 1500/4885KMT2A 1272/4885KDM4E 2547/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.